AFFYMETRIX (AFFX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX)

AFFX 14.01

0.0%

Apr 1 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (404)	7/4/1997 7:13:00 AM
From: wolfgangl	of 1728

Vector1, would you be so kind and give me the reference of this p53 story, if there is any. Did they write in which case the test would be performed? Is it suitable for screening whole populations and detecting cancer early enough for therapy? I can not imagine right that. Either you know the tumor and get tissue by biopsy or you do not and hardly could get enough cells/DNA from a bloodsample. When knowing the exact damage of individual p53 gene, you do not have the corresponding gene therapy yet. Either Millennium or Incyte are developing a gene activation therapy, which could in some cases restore expression of p53 perhaps. Did you hear more about it? Why should one not prefer BMY over the other ones. They will profit from those developements having this alliance but earn a lot and pay dividend. Wolfgang

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next